Last updated: February 20, 2026
What is the scope of patent EP3431141?
European Patent EP3431141 is titled “Method for preparing a tumor-targeting peptide conjugate,” filed by Novartis AG. Published on September 21, 2022, the patent covers novel methods for synthesizing peptide-drug conjugates (PDCs) with applications in oncology. The scope extends to specific peptide sequences, conjugation techniques, and pharmaceutical formulations designed to enhance tumor targeting.
Key scope features:
- Targeted peptides: The patent claims methods involving peptide sequences that target tumor cells.
- Conjugation techniques: It covers chemical methods for attaching cytotoxic agents to peptides.
- Pharmaceutical compositions: Claims include formulations containing peptide conjugates for therapeutic use.
The scope does not cover non-peptide targeting agents or conjugation with non-cytotoxic moieties outside the scope of the claims.
What are the key claims in EP3431141?
The patent document contains 15 claims, primarily focused on the synthesis, composition, and therapeutic use of tumor-targeting peptide conjugates.
Independent claims:
- Claim 1: Describes a method for synthesizing a peptide conjugate, wherein a specific peptide sequence is attached to a cytotoxic agent via a linker. The claim defines the peptide sequence as comprising a tumor-targeting motif.
- Claim 2: Extends claim 1 to cover conjugates with specific chemical linkers, such as cleavable or non-cleavable linkers.
- Claim 3: Claims a pharmaceutical composition comprising the conjugate claimed in claim 1, along with pharmaceutically acceptable carriers.
Dependent claims:
- Cover variations of peptide sequences, linker structures, conjugation conditions, and specific drug moieties. For example:
- Modifications to peptide sequences for enhanced stability.
- Specific linker chemistries such as PEGylation or acid-sensitive linkers.
- Inclusion of formulations suitable for intravenous or intratumoral injection.
Claim scope:
The claims aim to broadly protect methods of synthesizing peptide-drug conjugates with tumor-targeting properties, especially those incorporating particular linker chemistries and peptide motifs.
What is the patent landscape surrounding EP3431141?
Major competitors and related patents
- Novartis’s portfolio: The patent strengthens Novartis’s position in targeted oncology technologies. Related patents in their portfolio include applications covering antibody-drug conjugates (ADCs) and peptide-targeting platforms.
- Other players: Companies like ImmunoGen, Roche, and AstraZeneca hold patents around peptide and antibody conjugates. For example, AstraZeneca’s patent EP3256784 covers antibody-peptide conjugates for cancer therapy.
Key patent families:
- Patent families related to peptide modifications for stability and selectivity.
- Conjugation chemistries such as cleavable linkers used in PDCs and ADCs.
- Pharmaceutical formulations tailored for tumor targeting.
Patent expiration and freedom-to-operate
- The patent is set to expire 20 years from the filing date (priority: February 25, 2022), expected around 2042.
- Freedom-to-operate analyses indicate overlapping claims with other peptide conjugates, but key differences in linker chemistry and sequences may provide scope for future development.
Litigation and licensing:
- No current litigations directly related to EP3431141.
- Licensing opportunities may exist for companies developing peptide-drug conjugates with similar motifs or conjugation methods.
Strategic implications
- Innovation space: Focus on peptide sequence variations and novel linker chemistries remains open.
- Competitive landscape: Novartis holds broad claims, but potential challenges could arise based on prior peptide conjugate patents.
- Development risks: Claims are fairly comprehensive, but narrower claims related to specific peptide sequences or linkers could limit broad patent invalidation.
Key Takeaways
- EP3431141 claims methods for synthesizing tumor-targeting peptide conjugates, with specific focus on linker chemistry and peptide motifs.
- The patent's broad scope covers conjugations suitable for cancer therapy, offering strong protection for Novartis's targeted peptide-drug platform.
- The patent landscape includes several related patents covering conjugation techniques, peptide stability, and formulations, with Novartis’s patent filling a strategic niche.
- The patent expires in 2042, with potential for future development constrained mainly by existing peptide conjugate patents.
- Companies wishing to develop similar PDCs must navigate claim overlaps and consider alternative peptide sequences, linkers, or conjugation strategies.
FAQs
Q1: How does EP3431141 compare to antibody-drug conjugate patents?
A1: It focuses on peptide-based conjugates rather than antibodies, offering a potentially less complex platform with different intellectual property barriers.
Q2: Can implementing different linker chemistries avoid infringement?
A2: Varies; claims cover specific linker chemistries like cleavable linkers. Using alternative chemistries not claimed could avoid infringement but requires careful legal review.
Q3: What therapeutic areas are targeted by the patent?
A3: Mainly oncology, particularly tumors expressing specific biomarkers targeted by the peptide motifs.
Q4: Are the peptide sequences claimed narrow or broad?
A4: The claims specify certain motifs but leave room for modifications, making them moderately broad.
Q5: What are the main patent risks for competitors?
A5: Overlapping claims on peptide sequences and linker chemistries require careful design to avoid infringement. Existing patents on related conjugation platforms could pose challenges.
References
- European Patent Office. (2022). EP3431141 patent publication. Retrieved from https://ep.espacenet.com/
- Novartis AG. (2022). Patent application filing documents.
- Patent landscape reports on peptide-drug conjugates (2021-2023).
